TB-500, actin and thymosin beta-4

Ac-LKKTETQ

TB-500 is the synthetic seven-amino-acid fragment Ac-LKKTETQ: acetylated Leu-Lys-Lys-Thr-Glu-Thr-Gln. It corresponds to residues 17-23 of thymosin beta-4, the full 43-amino-acid protein. The short sequence carries an actin-binding motif. The review of thymosin beta-4 supplies the biological setting for the repair claims.

The small fragment tempts a convenient assumption: saving most of the protein’s work in a shorter chain. That is an assumption I distrust without a direct test. The catch appears when the results are assigned: most efficacy experiments used full-length thymosin beta-4. The fragment weighs about 889 daltons; the full protein about 4,963 daltons. The comparison diagram gives those chain lengths their proper proportions.

Actin sequestration

Actin helps a cell hold its shape and move. The free units of actin can assemble into filaments; full-length thymosin beta-4 binds those units and holds them in reserve. The 2004 structural study examined a gelsolin–thymosin beta-4 hybrid bound to actin at 2-angstrom resolution. It established a 1:1 complex and capping at both ends of the actin monomer, preventing polymerization.

The restraint fascinates me. A molecule associated with movement also prevents assembly under these conditions. A reserve of unassembled actin helps regulate the cell’s changing framework. The full protein’s structural behaviour is well described; the range of effects reproduced by the isolated TB-500 fragment remains a separate experimental question.

Skin wounds in rats

In the 1999 full-thickness rat wound experiment, full-length thymosin beta-4 increased re-epithelialization—the resurfacing of a wound—by 42% at four days and up to 61% at seven days versus saline. Wound contraction, collagen deposition and angiogenesis also increased. In the cell work, as little as 10 picograms stimulated keratinocyte migration two-to-three-fold.

There are several outcomes here, each describing a different job within healing. The multiple outcomes impress me more than any single percentage, although every percentage here describes that rat model. They supply no measured human benefit for TB-500.

Heart studies and uneven animal results

The mouse cardiac study reported that thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase, activating Akt. Following coronary artery ligation, early heart-muscle-cell survival and cardiac function improved. This experiment used the full protein.

The broader preclinical picture is uneven. The research review discusses a dystrophin-deficient mouse study in which regenerating muscle fibres increased without improvements in muscle strength, cardiac function or fibrosis. Those findings limit a sweeping account of regeneration.

A rat embolic-stroke experiment adds another complication: full-length thymosin beta-4 improved neurological function at 2 and 12 mg/kg, whereas 18 mg/kg produced no significant benefit. After that result, a simple more-is-better argument has lost my confidence.

The human protein study

The randomized Phase 1 trial enrolled 40 healthy volunteers and tested intravenous full-length thymosin beta-4. Study amounts were 42, 140, 420 or 1260 mg, with a single dose followed by daily administration for 14 days. Adverse events were infrequent and mild-to-moderate; no serious adverse events or dose-limiting toxicities were reported. Pharmacokinetics were dose-proportional, and half-life increased with dose.

That trial gives a human safety observation for its preparation and study conditions. The TB-500 heptapeptide has no completed controlled human clinical trials establishing safety or efficacy. I cannot transfer the larger protein’s reassuring result to the fragment.

Safety and sporting status

The thymosin beta-4 review describes pro-migratory and pro-angiogenic biology. The literature also associates the parent protein with tumour progression and tumour angiogenesis, raising a theoretical concern about unwanted tissue growth. That concern has not been measured as a TB-500 cancer risk in humans.

The 2026 sports-medicine review describes scarce rigorous human safety data for unapproved peptides and the possibility of serious harm. TB-500 has no FDA approval, no approved therapeutic indication and a WADA prohibition. Unregulated research material also brings uncertainty about identity, purity and sequence. These are substantial unanswered questions, even when the cellular biology is persuasive.